Device profile of the EVOQUE Eos system for transcatheter mitral valve replacement: a brief narrative review.

INTRODUCTION

Severe mitral regurgitation (MR) poses significant therapeutic challenges, especially in patients at high surgical risk or unsuitable for transcatheter edge-to-edge repair (TEER). Transcatheter mitral valve replacement (TMVR) has emerged as a viable alternative, with the EVOQUE Eos system representing a next-generation, fully retrievable, transseptal TMVR platform tailored to address prior limitations in safety, anatomical fit, and procedural control.

AREAS COVERED: This review outlines the design features, procedural considerations, and early clinical performance of the EVOQUE Eos TMVR system, referencing results from the first-in-human experience and the ongoing MISCEND trial. Furthermore, the EVOQUE Eos is compared with other contemporary TMVR systems. Procedural challenges such as paravalvular leak, left ventricular outflow tract (LVOT) obstruction, bleeding, and hypoattenuated leaflet thickening (HALT) are discussed in context.

EXPERT OPINION: The EVOQUE Eos system marks a pivotal advancement in TMVR by offering fully percutaneous access, intuitive deployment, and retrievability. While early outcomes are encouraging, further data are needed to guide patient selection, antithrombotic management, and long-term valve durability. The system may play a central role in the expanding treatment landscape for MR, potentially transforming standard practice in the coming years.